Fig. 3: Clinical outcomes of the dual-matched therapy.
From: Gene- and immune-targeted therapy combinations using dual-matched biomarkers for patient selection
A Clinical benefit rate (SD ≥ 6 months/CR/PR) of the 17 patients who underwent dual-matched therapy was 53% (9/17). B The swimmer’s plot provides information on the duration of survival and the timing of progression for each patient. The arrow indicates that the patients were progression-free at the date of their last follow-up. Two patients did not show apparent progression, but their therapy was suspended due to an adverse event (ID 8) or lost to follow-up (ID 17). C, D Kaplan–Meier curves for progression-free survival (PFS, Panel C) and overall survival (OS, Panel D) of 17 patients who received dual-matched therapy for treatment-refractory diverse cancers. Median follow-up period was 8.1 months (range 2.1–62.1). The pale red area indicates the 95% confidence interval (CI). Median PFS was 6.1 months (95% CI, 2.9–not estimable), and median OS was 9.7 months (95% CI, 6.7–not estimable). CNS central nervous system, CR complete response, PD progressive disease, PR partial response, SD stable disease.
